Axsome Therapeutics Reports Its First Quarter Since Doubling Down on Sales Infrastructure

Axsome Therapeutics (AXSM) is scheduled to report first-quarter 2026 earnings before market open on Monday, May 4, 2026, with analysts expecting a loss of $0.85 per share. The central question for investors is whether the company's commercial execution can continue narrowing losses while advancing its CNS-focused pipeline—a critical inflection point as the Street projects a dramatic swing to profitability in 2027. With the stock trading at $206.53 and Wall Street's consensus target at $225.15, this report will test whether AXSM's momentum can sustain its recent technical breakout above all major moving averages.

Part 1: Earnings Preview

Axsome Therapeutics is a biopharmaceutical company developing and commercializing therapies for central nervous system disorders, with its lead product Auvelity (for major depressive disorder) driving revenue growth alongside Sunosi (for excessive daytime sleepiness) and a pipeline including AXS-07 for migraine. The company serves a critical unmet need in neuropsychiatric conditions where treatment options remain limited.

For the quarter ending March 2026, analysts expect AXSM to report a loss of $0.85 per share on consensus revenue estimates around $190 million. The company most recently reported Q4 2025 results with an EPS of -$0.71, beating the estimate of -$0.70 by a penny. Compared to the same quarter last year (Q1 2025: -$0.80), the current estimate of -$0.85 represents a 6.25% deterioration year-over-year, though this likely reflects increased investment in pipeline development and commercial expansion.

Three key themes define this earnings story:

Auvelity Commercial Trajectory: Investors will scrutinize prescription trends and market share gains for Auvelity, which has been the primary growth driver. Quarterly revenue progression, patient retention rates, and formulary wins will signal whether the company can sustain its momentum in the competitive antidepressant market. Any commentary on payer coverage expansion or reimbursement improvements will be critical.

Path to Profitability: With analysts projecting a dramatic swing from a -$1.05 loss in 2026 to $5.53 earnings in 2027 (a 627% improvement), this report must demonstrate operating leverage and a credible roadmap to positive cash flow. Investors will parse gross-to-net deductions, operating expense discipline, and whether the company can achieve profitability without additional capital raises.

Pipeline Progress and Regulatory Milestones: Updates on late-stage assets—particularly AXS-07 for migraine and any new indication expansions—will shape the long-term narrative. Clinical trial readouts, FDA interactions, and timelines for potential new product launches will determine whether AXSM can diversify beyond Auvelity and Sunosi to justify its current valuation.

Leading analysts remain overwhelmingly bullish, with 18 of 22 rating the stock a Strong Buy and price targets ranging from $200 to $260. The consensus view emphasizes AXSM's commercial execution and the significant earnings inflection expected in 2027, though some caution that the path to profitability requires flawless execution on both revenue growth and cost management.

Part 2: Historical Earnings Performance

Axsome Therapeutics has demonstrated a mixed but generally improving earnings track record over the past four quarters. In Q1 2025, the company reported -$0.80 against an estimate of -$1.26, delivering a substantial +36.51% beat—the strongest positive surprise in the recent period. Q2 2025 continued the trend with -$0.92 versus -$1.00 expected (+8.00% beat), suggesting improving operational performance.

However, the pattern shifted in the second half of 2025. Q3 brought a -$0.94 result against a -$0.82 estimate, marking a -14.63% miss—the only significant disappointment in the four-quarter window. Q4 2025 essentially met expectations with -$0.71 versus -$0.70 estimated, a marginal -1.43% miss that was effectively in-line.

The overall pattern reveals a company that exceeded expectations meaningfully in the first half of 2025 as Auvelity gained commercial traction, stumbled slightly in Q3 (possibly due to higher-than-expected operating expenses or slower prescription growth), then stabilized in Q4. The trend suggests AXSM is narrowing losses faster than analysts initially projected, though the Q3 miss serves as a reminder that the path to profitability remains uneven. Investors should watch whether Q1 2026 returns to the beat pattern or continues the more conservative performance seen in the latter half of 2025.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Axsome Therapeutics typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior shows moderate volatility around AXSM earnings, with an average absolute Day 0 move of 3.41% and Day +1 follow-through of 2.06%. Intraday ranges are notably wider, averaging 9.06% on Day 0 and 4.90% on Day +1, indicating significant intraday swings even when closing moves are more contained.

The most recent report (February 23, 2026) saw a -4.88% Day 0 decline despite beating estimates, with an 8.45% intraday range—suggesting initial disappointment (possibly guidance-related) followed by some recovery. The November 2025 report was relatively muted (+0.56% Day 0) despite a miss, while August 2025 delivered a +3.42% gain on a beat. The largest reaction came in November 2024 with a +9.35% surge, demonstrating that material beats or positive guidance can drive outsized moves.

The pattern suggests AXSM's post-earnings behavior is highly result-dependent rather than directionally predictable, with guidance and forward commentary often mattering as much as the headline beat/miss. Investors should prepare for potential intraday volatility exceeding 9% even if the closing move is more modest, and recognize that beats don't guarantee rallies if the outlook disappoints.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.90% ($14.25) through the May 15 monthly expiration, which is notably higher than the average historical Day 0 move of 3.41% but well below the average intraday range of 9.06%. This suggests options traders are anticipating above-average volatility for this report, possibly reflecting uncertainty around the profitability timeline and pipeline updates, though the implied move remains within the historical range of post-earnings swings AXSM has demonstrated.

Part 3: What Analysts Are Saying

Analyst sentiment on Axsome Therapeutics is overwhelmingly bullish, with a consensus rating of 4.73 out of 5.00—firmly in Strong Buy territory. The breakdown shows 18 Strong Buys, 2 Moderate Buys, and 2 Holds, with zero sell ratings. This reflects broad confidence in the company's commercial trajectory and pipeline potential.

The average price target of $225.15 implies 9.0% upside from the current price of $206.53, with a range spanning $200 to $260. The high-end target suggests some analysts see potential for 25.9% appreciation if execution exceeds expectations, while even the most conservative $200 target sits near current levels, indicating limited perceived downside among the analyst community.

Sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 4.73. This stability suggests analysts are maintaining conviction heading into the report rather than adjusting positions preemptively, likely awaiting confirmation of commercial trends and pipeline progress before revising models. The lack of downgrades despite the stock's recent rally above $200 indicates the Street believes current valuation remains justified by the 2027 profitability outlook.

Part 4: Technical Picture

Axsome Therapeutics enters earnings with exceptionally strong technical momentum, reflected in the Barchart Technical Opinion showing a 100% Buy signal—up dramatically from 48% Buy a month ago. This surge in technical conviction coincides with the stock breaking out above all major moving averages, signaling a decisive shift in trend.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum as the stock extends its breakout
• Medium-term (100% Buy): Equally strong reading confirms the uptrend is established across intermediate timeframes, not just a short-term spike
• Long-term (100% Buy): Maximum conviction across all timeframes suggests a structural shift in the stock's trajectory, with long-term trend now firmly positive

Trend Characteristics: The combination of Maximum strength and Strongest direction indicates AXSM is in an unusually powerful uptrend heading into earnings, with technical conditions as favorable as they can be—though this also raises the bar for results to sustain momentum.

The stock is trading above all key moving averages, with the current price of $206.53 sitting well above the 200-day MA at $147.56 (+40.0%), the 100-day at $171.39 (+20.5%), and even the short-term 5-day at $194.13 (+6.4%). This clean breakout above resistance levels suggests strong institutional accumulation and positions the stock favorably for a continuation rally if earnings deliver positive surprises. However, the extended nature of the move—particularly the 40% premium to the 200-day average—means any disappointment could trigger profit-taking back toward the $185-$190 support zone where the 20-day MA resides. The overall setup is supportive but stretched, rewarding bulls if results confirm the optimism but offering limited margin for error given the recent run.